Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FR alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
To compare progression-free survival after platinum-based chemotherapy (doublet) plus bevacizumab and randomized to maintenance mirvetuxemab sorvtansine (MIRV) plus bevacizumab (Arm 1) versus bevacizumab alone (Arm 2)
DiagnosisHigh-grade serous ovarian, primary peritoneal, or fallopian tube cancer.
Platinum-sensitive. 1 prior line of therapy. FR alpha high (>/= 75%). Tumor tissue testing required.
Maintenance mirvetuxemab sorvtansine (MIRV) plus bevacizumab (Arm 1) versus bevacizumab alone (Arm 2)
For more information visit Clinicaltrials.gov